Suppr超能文献

用于长期瘤内释放的RGD修饰的聚乙二醇-聚酰胺-胺-阿霉素共轭物的可生物降解聚合物植入物的研发。

Development of biodegradable polymeric implants of RGD-modified PEG-PAMAM-DOX conjugates for long-term intratumoral release.

作者信息

Wang Ke, Zhang Xiaofeng, Zhang Lihong, Qian Lili, Liu Chang, Zheng Jiajun, Jiang Yanyan

机构信息

Key Laboratory of Smart Drug Delivery, Ministry of Education & PLA, School of Pharmacy, Fudan University , Shanghai , People's Republic of China and.

出版信息

Drug Deliv. 2015 May;22(3):389-99. doi: 10.3109/10717544.2014.895457. Epub 2014 Mar 27.

Abstract

CONTEXT

The sustained release implants can be directly implanted in tumor site by surgery and are promising for cancer treatment.

OBJECTIVE

RGD-modified PEGylated polyamidoamine (PAMAM) dendrimer with doxorubicin (DOX) conjugated by acid-sensitive linkage (RGD-PPCD) was a potential conjugate for tumor-targeted therapy. In order to enhance tumor retention ability and long-term effect of drug, we developed the DOX and its conjugate implants using poly(dl-lactic-co-glycolic acid) (PLGA), poly(dl-lactic acid) (PLA) and polyethylene glycol (PEG) as carrier materials.

METHODS

The implants were prepared by a simple solvent evaporation method. Different formulations with varying ratios of three polymers were designed, prepared and evaluated on the basis of viscosity, in vitro release and drying time. Furthermore, in vivo biodistribution and antitumor activity of the implants were studied in mice with subcutaneous C6 xenografts.

RESULTS

The optimized formulation was obtained with the 3:1 ratio of PLGA/PLA (w/w) and 1% PEG (wt.%). The drug release behavior of DOX, PPCD and RGD-PPCD implants prepared by the optimized formulation was similar according to the assessment of similarity factor f2, and the release curves were fell into three phases, including a lag-period, then the second phase which was consistent with zero-order model followed by a plateau. Data of total DOX remained in implants indicated the release were faster in vivo than in vitro. Moreover, intratumoral drug amount of RGD-PPCD implants was the highest 45 days after implantation. Correspondingly, the RGD-PPCD implants exhibited the strongest antitumor activity compared with PPCD and free DOX implants.

DISCUSSION AND CONCLUSION

This paper presents an exploratory research on macromolecule-drug conjugates, including RGD-PPCD and PPCD, which have the potential to be developed into long-term effect implants for tumor therapy with high efficiency and low systematic toxicity.

摘要

背景

缓释植入剂可通过手术直接植入肿瘤部位,在癌症治疗方面具有广阔前景。

目的

经酸敏感连接子偶联阿霉素(DOX)的RGD修饰聚乙二醇化聚酰胺-胺(PAMAM)树枝状大分子(RGD-PPCD)是一种潜在的肿瘤靶向治疗偶联物。为提高药物的肿瘤滞留能力和长期疗效,我们以聚(dl-乳酸-共-乙醇酸)(PLGA)、聚(dl-乳酸)(PLA)和聚乙二醇(PEG)为载体材料,研发了DOX及其偶联物植入剂。

方法

采用简单的溶剂蒸发法制备植入剂。设计、制备并基于粘度、体外释放和干燥时间评估了三种聚合物不同比例的不同配方。此外,在皮下接种C6异种移植瘤的小鼠中研究了植入剂的体内生物分布和抗肿瘤活性。

结果

获得了PLGA/PLA比例为3:1(w/w)且PEG含量为1%(wt.%)的优化配方。根据相似因子f2评估,由优化配方制备的DOX、PPCD和RGD-PPCD植入剂的药物释放行为相似,释放曲线分为三个阶段,包括一个滞后期,随后是符合零级模型的第二阶段,接着是一个平台期。植入剂中总DOX残留数据表明,体内释放比体外更快。此外,RGD-PPCD植入剂在植入后45天瘤内药物量最高。相应地,与PPCD和游离DOX植入剂相比,RGD-PPCD植入剂表现出最强的抗肿瘤活性。

讨论与结论

本文对大分子药物偶联物进行了探索性研究,包括RGD-PPCD和PPCD,它们有潜力被开发成具有高效和低全身毒性的肿瘤治疗长效植入剂。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验